Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I. Santin AD, et al. Among authors: elbi c. Int J Gynecol Cancer. 2023 Apr 3;33(4):562-570. doi: 10.1136/ijgc-2022-003927. Int J Gynecol Cancer. 2023. PMID: 36564099 Free PMC article. Clinical Trial.
Targeting mesothelin in cancer.
Elbi C. Elbi C. Mol Ther Oncolytics. 2023 Dec 3;31:100756. doi: 10.1016/j.omto.2023.100756. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38075245 Free PMC article. No abstract available.
Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma.
Cleeland CS, Keating KN, Cuffel B, Elbi C, Siegel JM, Gerlinger C, Symonds T, Sloan JA, Dueck AC, Bottomley A, Wang XS, Williams LA, Mendoza TR. Cleeland CS, et al. Among authors: elbi c. Sci Rep. 2024 Jun 27;14(1):14839. doi: 10.1038/s41598-024-62307-5. Sci Rep. 2024. PMID: 38937473 Free PMC article. Clinical Trial.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Kindler HL, Novello S, Bearz A, Ceresoli GL, Aerts JGJV, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Calabrò L, Burgers JA, Santoro A, Cedrés S, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G Jr, Siegel JM, Kasten L, Köchert K, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA. Kindler HL, et al. Among authors: elbi c. Lancet Oncol. 2022 Apr;23(4):540-552. doi: 10.1016/S1470-2045(22)00061-4. Lancet Oncol. 2022. PMID: 35358455 Free PMC article. Clinical Trial.
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R, Blumenschein GR Jr, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. Hassan R, et al. Among authors: elbi c. J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26. J Clin Oncol. 2020. PMID: 32213105 Free PMC article. Clinical Trial.
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA. Quanz M, et al. Among authors: elbi c. Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135. eCollection 2018 Sep 25. Oncotarget. 2018. PMID: 30344925 Free PMC article.
Turkish Ministry of Health, 2nd Turkish Medical General Assembly Clinical Oncology Study Group Report.
Özmen V, Dağoğlu N, Dede İ, Akçakaya A, Kerem M, Göksel F, Özgür E, Başkan E, Yaylacı M, Ceydeli A, Baykara M, Kızıltan HŞ, Kömürcü Ş, Gümüş M, Türk HM, Demirhan R, Akgün A, Kadoglou N, Yatman E, Elbi CC, Güleç S, Soran A, Özet A, Keleştimur F. Özmen V, et al. Among authors: elbi cc. J Breast Health. 2016 Jan 1;12(1):9-17. doi: 10.5152/tjbh.2015.2869. eCollection 2016 Jan. J Breast Health. 2016. PMID: 28331725 Free PMC article.
33 results